Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- PMID: 22452896
- DOI: 10.1016/S1470-2045(12)70087-6
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Erratum in
- Lancet Oncol. 2012 May;13(5):e186
Abstract
Background: Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors. We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.
Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncology Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 weeks of treatment with erlotinib or gefitinib. We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care. Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2). Investigators, patients, and the trial sponsor were masked to treatment assignment. The primary endpoint was overall survival (from date of randomisation to death), analysed on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00656136.
Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo). Median overall survival was 10·8 months (95% CI 10·0-12·0) in the afatinib group and 12·0 months (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74). Median progression-free survival was longer in the afatinib group (3·3 months, 95% CI 2·79-4·40) than it was in the placebo group (1·1 months, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001). No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group. Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group. The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3). These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2. Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group. We recorded two possibly treatment-related deaths in the afatinib group.
Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.
Funding: Boehringer Ingelheim Inc.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Comment in
-
A new generation of EGFR tyrosine-kinase inhibitors in NSCLC.Lancet Oncol. 2012 May;13(5):442-3. doi: 10.1016/S1470-2045(12)70124-9. Epub 2012 Mar 26. Lancet Oncol. 2012. PMID: 22452893 No abstract available.
Similar articles
-
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5. Lancet Oncol. 2015. PMID: 26156651 Clinical Trial.
-
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12. Lancet Oncol. 2016. PMID: 27083334 Clinical Trial.
-
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.Lancet Oncol. 2012 May;13(5):539-48. doi: 10.1016/S1470-2045(12)70086-4. Epub 2012 Mar 26. Lancet Oncol. 2012. PMID: 22452895 Clinical Trial.
-
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2021 Mar 18;3:CD010383. doi: 10.1002/14651858.CD010383.pub3. PMID: 27223332 Updated. Review.
-
Gefitinib for advanced non-small cell lung cancer.Cochrane Database Syst Rev. 2018 Jan 16;1(1):CD006847. doi: 10.1002/14651858.CD006847.pub2. Cochrane Database Syst Rev. 2018. PMID: 29336009 Free PMC article. Review.
Cited by
-
Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.Target Oncol. 2024 Jul;19(4):547-564. doi: 10.1007/s11523-024-01073-w. Epub 2024 Jun 1. Target Oncol. 2024. PMID: 38824269
-
Mechanism of targeting the mTOR pathway to regulate ferroptosis in NSCLC with different EGFR mutations.Oncol Lett. 2024 May 1;28(1):298. doi: 10.3892/ol.2024.14431. eCollection 2024 Jul. Oncol Lett. 2024. PMID: 38751752 Free PMC article.
-
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss.Heliyon. 2024 Apr 17;10(9):e29668. doi: 10.1016/j.heliyon.2024.e29668. eCollection 2024 May 15. Heliyon. 2024. PMID: 38698967 Free PMC article.
-
Discovery of potential epidermal growth factor receptor inhibitors from black pepper for the treatment of lung cancer: an in-silico approach.In Silico Pharmacol. 2024 Apr 8;12(1):28. doi: 10.1007/s40203-024-00197-1. eCollection 2024. In Silico Pharmacol. 2024. PMID: 38601803
-
Oncogenic alterations in advanced NSCLC: a molecular super-highway.Biomark Res. 2024 Feb 12;12(1):24. doi: 10.1186/s40364-024-00566-0. Biomark Res. 2024. PMID: 38347643 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous